Sponsor or institution
Clinical trials and research at Hangzhou DAC Biotechnology Co., Ltd.
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Hangzhou DAC Biotechnology Co., Ltd. that are recruiting, in China. By phase: Phase 1 (4), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| DEC003M in Advanced Prostate Cancer | Phase 1 | Beijing, Beijing Municipality and 6 other locations | Recruiting | Jun 18, 2026 |
| DXC006 with immune therapy or platinum for small cell lung cancer | Phase 1/2 | Guangzhou, Guangdong | Recruiting | Apr 30, 2026 |
| DXC014 for adults with advanced solid tumors | Phase 1 | Beijing, Beijing Municipality and 4 other locations | Recruiting | Sep 17, 2025 |
| DXC008 treatment for prostate cancer and other solid tumors | Phase 1 | Changsha, Hunan and 3 other locations | Recruiting | Apr 13, 2025 |
| Evaluating DXC006 for patients with advanced solid tumors and blood cancers | Phase 1 | Hefei, Anhui and 4 other locations | Recruiting | Jan 25, 2024 |
All recruiting trials (5)
-
DEC003M in Advanced Prostate Cancer
This early-phase study tests DEC003M in adults with metastatic castration-resistant prostate cancer to see if it can be safely given and whether it shows signs of activity.
-
DXC006 with immune therapy or platinum for small cell lung cancer
This trial tests DXC006 in combination with an immune checkpoint inhibitor or platinum-based chemotherapy to see if it is safe and shows activity in adults with small cell lung cancer.
-
DXC014 for adults with advanced solid tumors
This will test DXC014, an experimental cancer medicine, in adults with advanced solid tumors including small cell lung cancer, melanoma, and prostate cancer.
-
DXC008 treatment for prostate cancer and other solid tumors
This phase 1 trial will test whether DXC008 is safe and shows early anti-cancer activity in adults with prostate cancer or other advanced solid tumors who have exhausted standard therapies.
-
Evaluating DXC006 for patients with advanced solid tumors and blood cancers
This study is testing a new treatment called DXC006 to see if it's safe and effective for adults with advanced solid tumors and blood cancers who haven't had success with other therapies.
Quick answers
How many clinical trials run by Hangzhou DAC Biotechnology Co., Ltd. are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 4, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.